Summary: Guidelines on proton craniospinal irradiation (p-CSI) target volume selection in children are lacking. We examined the impact of target volume selection on growth of children receiving p-CSI at a institution. Records of 58 patients who received p-CSI were reviewed. Median age at treatment initiation was 8 years (range, 2 to 18 y). Spinal target volumes included whole vertebral body (WVB) in 67% and partial vertebral body (PVB) in 33%. Height z-scores before and after p-CSI were assessed using Centers for Disease Control and Prevention stature-for-age charts. Maximal Cobb angle and height z-score change were compared for WVB versus PVB p-CSI using a t test. Among 93% of patients with detailed data, median follow-up was 19 months (range, 2 to 58 mo) after radiation therapy initiation. Quantitative growth evaluations were available for 64% of patients. Median change in height z-score was −0.5 (range, −2.1 to +0.7) after treatment, representing a decrease (P < 0.001) in age-adjusted height. WVB patients had significantly greater reduction in height z-score versus PVB patients (P = 0.004) but no difference in Cobb angle change (P > 0.05). Despite reluctance surrounding its use in younger patients, PVB p-CSI was associated with similar spinal curvature and less growth suppression as compared with WVB p-CSI; a trial comparing WVB versus PVB in children may be warranted.
C raniospinal irradiation (CSI) is an important component of therapy for children who are either at risk for or affected by disseminated disease throughout the neuraxis. However, use of CSI is associated with growth changes, particularly for younger patients. Radiation therapy (RT) to the vertebral body has been linked with the development of spinal curvature deformity. [1] [2] [3] In addition, while children treated with CSI can experience delayed-onset growth retardation secondary to endocrine abnormalities, spinedirected RT also leads to slowed vertebral body growth, leading to height deficits. [4] [5] [6] [7] Because of dose reduction to anterior structures, proton craniospinal irradiation (p-CSI) offers a potential reduction of long-term sequelae over photon CSI, including cardiac dysfunction, hypothyroidism, second malignancy, and growth suppression. [8] [9] [10] [11] [12] With current technology, 2 spinal target volume selection strategies are widely used for p-CSI: whole vertebral body (WVB) and partial vertebral body (PVB). For children at skeletal maturity, only the thecal sac is intentionally targeted; however, the posterior portion of the vertebral body is included the planning target volume to account for range uncertainties, leading to a functional PVB irradiation. For younger, growing children, PVB p-CSI is generally discouraged as it is hypothesized to cause lordosis and scoliosis as a result of dose asymmetry across the vertebral body. 1, 13 To reduce the risk of lateral vertebral body wedging and spinal curvature deformity associated with lateral dose asymmetry for growing children, 14, 15 the WVB is targeted. Nonetheless, the use of WVB p-CSI may potentially undermine potential advantages of using p-CSI, including preservation of bone marrow, sparing of the anterior weight-bearing spine and organs at risk, and suppression of growth.
Choice of WVB versus PVB in growing children receiving p-CSI to the whole spine remains controversial and practice patterns vary greatly. 1, 16 Owing to a paucity of published data, standardized guidelines on appropriate p-CSI target volume in children are lacking. We therefore report our early experience with dose selection, target volume selection, and early growth outcomes of children receiving p-CSI.
PATIENTS AND METHODS

Patient Population
This is a single-institution cohort of children treated with p-CSI. After approval by our internal Institutional Review Board, 58 patients aged 18 or younger at the time of treatment with p-CSI at our institution between 2012 and 2016 were identified. Sex composition was 69% male and 31% female. Median age at initiation of p-CSI treatment was 8 years (range, 2 to 18 y). Median age at treatment for males was 6 years (range, 2 to 14 y) for WVB and 15 years (range, 11 to 17 y) for PVB. For females, median age at treatment was 7 years (range, 6 to 11 y) for WVB and 13 years (range, 12 to 18 y) for PVB. The most common primary tumors were medulloblastoma (59%), pineoblastoma (10%), and neuroblastoma (9%); a complete list of primary diagnoses and frequencies can be found in Table 1. resonance images (MRI). Patients were positioned prone or supine for CSI and immobilized using an Aquaplast mold (Qfix Positioning, Avondale, PA) for the head and Alpha Cradle (Smithers Medical Products, North Canton, OH) for the torso.
The craniospinal target volume consisted of the whole brain plus the length of the spinal canal to the level of the inferior aspect of the thecal sac. In cases where a tumor bed boost was used, the clinical target volume consisted of the tumor bed and areas of gross disease plus a margin, while respecting anatomic boundaries. Multiple beam approaches were used to treat the whole brain, including opposed laterals, posterior obliques, and a single posteroanterior portal. The portals ensured adequate margin on the cribriform plate. The cranial and spinal fields were matched with a daily feathering junction using 3 to 4 match lines to spread out the hot spots and improve homogeneity in uniform scanning. Although utilizing pencil beam scanning, a gradient structure allowing for a gradual match line was used in lieu of feathered match lines. 17, 18 The majority of spine volumes were treated using a single posteroanterior beam, whereas some cases utilized left and right posterior oblique portals to treat the spine volume. Spinal target volumes were chosen based on multiple factors, including patient age, sex, and remaining growth potential. Target volumes along the entire spinal axis included WVB in 67% and PVB in 33%. Normal structures, including but not limited to the pituitary gland, hypothalamus, brainstem, and spinal cord were contoured and dose constraints were determined as per QUANTEC/Emami guidelines. Daily orthogonal radiographs were used to ensure accurate setup and younger children were given daily anesthesia. Treatment was delivered using a rotational gantry.
Treatment with p-CSI was administered for primary treatment in 91% of patients and for central nervous system relapse for 9%. As part of combined modality therapy, 79% received surgery and 12% received chemotherapy before p-CSI. Chemotherapy was administered concurrently with and/or after p-CSI in 72%. The p-CSI dose was prescribed in radiobiological gray equivalents (Gy[RBE]) using the relative biological effectiveness (RBE) value of 1.1, and dose was delivered in 1.8 Gy(RBE) fractions. Most common doses were 23.4, 36, and 18 Gy(RBE) used for 40%, 36%, and 16% of patients, respectively. Boost RT to ≥ 1 sites was additionally given to all patients with cumulative median dose 54 Gy(RBE) (range, 18 to 59.4 Gy[RBE]). Boosted sites were supratentorial in 36%, infratentorial in 67%, and spinal in 14%.
Endpoints and Statistical Analysis
The development of new-onset scoliosis was determined by physical examination at each follow-up visit and/or with imaging of the spine (MR spine, MR abdomen, CT scan, and/ or chest x-ray). For 16 patients (28%) for whom follow-up images were available, the maximum Cobb angle, defined as the maximum angle between lines extrapolated from rostral and caudal edges of a focus of scoliotic curvature, was measured. A Cobb angle of > 10 degrees was used to identify scoliosis. 16, 19 Cobb angles before and after treatment were compared using a t test. Cobb angle change was additionally compared between patients receiving WVB and PVB p-CSI.
Changes in height were assessed by comparing patient height at baseline and during follow-up visits. Baseline height was obtained <3 months before p-CSI. A z-score, a statistical measure of the number of standard deviations away from the population mean that a particular data value lies, was calculated for the baseline height and the latest follow-up height using the 2000 Centers for Disease Control and Prevention growth charts. Subsequently, paired t tests were performed to compare changes in height z-scores before and after p-CSI. A 2-tailed t test comparing z-score change in height between WVB and PVB p-CSI patients was also conducted. Linear regression with suppressed constant was used to assess change in height z-score versus follow-up interval. Multivariate linear regression with suppressed constant adjusted for follow-up interval, sex, disease relapse status, p-CSI dose, target volume, and age at treatment was also performed.
Statistical analysis was performed with Microsoft Excel 2016 (Microsoft, Redmond, WA) and Stata Version 13.0 (StataCorp, College Station, TX). A P ≤ 0.05 using a 2-sided hypothesis was used to determine significance for all comparisons.
RESULTS
Detailed follow-up data were available for 93% of patients with a median follow-up of 19 months (range, 2 to 58 mo) after RT initiation; data availability is displayed in Figure 1 . Examination of the spine for curvature was conducted in 64% of patients with physical examination and imaging (59% spine MRI, 3% CT abdomen/pelvis, 2% chest x-ray) and in 29% of patients as part of physical examination only. Among patients with radiographic evaluation, new-onset MRI abnormalities included straightening of cervical lordosis (4%) and mild midthoracic scoliotic curvature (2%). No patients developed clinical or radiographic evidence of lordosis or scoliosis. In 28% of patients for whom maximum Cobb angles were calculated, the median was 2.7 (range, 0.7 to 5.9) degrees before treatment and 3.8 (range, 1.2 to 9.4) degrees after treatment. A t test of pretreatment and posttreatment yielded a significant increase in maximum Cobb angle (P < 0.01). However, no patient met the scoliosis diagnostic criterion of a Cobb angle of ≥ 10 degrees at any time. Median Cobb angle change for patients receiving WVB was +0.8 (range +0.2 to +7.2) degrees and for patients receiving PVB was +1.4 (range, −0.8 to +4.7) degrees; no difference was found on t test (P = 0.56). Quantitative growth curve evaluations were available for 37 patients (64%). At baseline, the median height percentile and z-score was 43.2% (range, 0.3% to 91.5%) and −0.3 (range, −2.8 to +1.2). With median interval between height measurements of 24 months (range, 3 to 58 mo), the median height percentile and z-score posttreatment was 24.4% (range, 0.3% to 85.8%) and −0.8 (range, −2.9 to +1.1), representing a decrease (P < 0.001) in age-adjusted height compared with baseline. The median change in height z-score was −0.5 (range, −2.1 to +0.7). Z-score change after treatment was negative for 32 patients and positive for 5 patients. A comparison of height z-scores before and after FIGURE 2. Boxplots of height z-scores before and after WVB p-CSI (A), and PVB p-CSI (B), and connected scatterplots of height z-scores before and after WVB p-CSI (C) and PVB p-CSI (D). Median change in height z-score among WVB patients was −0.6 (range, −2.1 to +0.7) and among PVB patients was −0.2 (range, −1.2 to +0.7); a significant difference between these groups was found on t test (P = 0.004). p-CSI indicates proton craniospinal irradiation; PVB, partial vertebral body; RT, radiation therapy; WVB, whole vertebral body.
treatment for WVB and PVB p-CSI are displayed in box plot and connected scatterplot forms in Figure 2 . Median change in height z-score among WVB patients was −0.6 (range, −2.1 to +0.7) and among PVB patients was −0.2 (range, −1.2 to +0.7); a significant difference between these groups was found on t test (P = 0.004).
Univariate linear regression analysis evaluating change in height z-score versus follow-up interval is displayed in Figure 3 , with resulting equation Δz = −0.25t, where Δz represents the change in height z-score after p-CSI and t represents the follow-up interval between height measurements in years (R 2 = 0.16; P < 0.0001). On multivariate linear regression, significant negative contributions to change in height z-score were identified for follow-up interval and dose in Gy(RBE) and positive contribution was identified for age at p-CSI treatment (P < 0.005). In the multivariate model, a year of follow-up after p-CSI was associated with a −0.23 change in height z-score (95% confidence interval [CI], −0.37 to −0.09). An increase in dose of 10 Gy(RBE) was associated with a height z-score change of −0.34 (95% CI, −0.56 to −0.12). An incremental 5 years of age at diagnosis was associated with a height z-score change of +0.43 (95% CI, +0.20 to +0.67). Sex, relapse status, use of concurrent/adjuvant chemotherapy, and target volume were not associated with change in height z-score. Regression results are displayed in Table 2 .
DISCUSSION
Dose and target volume selection in p-CSI for pediatric patients may be guided by disease characteristics, comorbidities, age, sex, and remaining growth potential, with the goal of controlling disease while minimizing deformity. Although several studies have advocated for including the WVB in patients under 15 years of age, [20] [21] [22] approximating the age of skeletal maturity, the approach is ultimately physiciandependent and patient-dependent. In our study, all patients aged below 10 years received WVB p-CSI, whereas those aged above 14 years received PVB p-CSI. Target volumes for patients aged 10 to 14 years were given more careful consideration and chosen based on patient characteristics and preferences elicited after informed consent with patients' families.
The risk of posttreatment scoliosis is the most common reason for including the WVB in the target volume for p-CSI in growing children, but it is unclear whether WVB p-CSI mitigates this risk. Potential risk factors for scoliosis with RT to any part of the spine include dose > 24 Gy and larger field size. 3, 16 Previous literature has documented late effects of photon RT to the spine for Wilms tumor, neuroblastoma, and medulloblastoma, with long-term rates ranging between 40% to 50% for pediatric patients despite the inclusion of the WVB in the target volume. 1 Among patients treated with PVB p-CSI to the entire spine, one study by MacEwan and colleagues with a median follow-up of over 13 years reported that 2 of 5 pediatric medulloblastoma patients developed scoliosis. Although we report a statistically significant increase in Cobb angle after treatment, we did not find any instances of clinically or radiographically diagnosed scoliosis at a median follow-up of ∼1.5 years, reaffirming that scoliosis is not a common early effect of p-CSI. However, we also did not find any difference in Cobb angle change between patients receiving WVB versus PVB p-CSI, suggesting that PVB p-CSI may not be associated with greater development of scoliosis.
Our study shows that the effects on age-adjusted height may be seen shortly after p-CSI treatment. Time to followup was significantly associated with a decrease in height z-score, both on univariate and multivariate analysis, reflecting the impact of both target volume strategies on epiphyseal growth plates. Age at treatment and RT dose were also associated with change in height z-score, as has been shown for photon CSI in previous studies. 2, 5, 6, 23 However, other attributes such as sex, relapse status, chemotherapy, and target volume were not associated with change in height z-score. These results suggest that the effect of RT on the ossification centers of the vertebrae may more profoundly suppress growth than other factors in the immediate post-RT period. Our findings regarding PVB p-CSI suggest that it is a potentially superior target volume strategy even for younger patients, as its effects on growth suppression and lateral spinal curvature deformity may be noninferior to those for WVB p-CSI. Although longer follow-up with this cohort of patients is needed to confirm these findings, the potential benefits of PVB p-CSI include reduction of both short-term and long-term toxicity and secondary malignancy. 9 Although there has been reluctance to pursue PVB p-CSI given the concern of scoliosis, our data show that it may be feasible and safe in children; a clinical 24 but a direct headto-head comparison of WVB versus PVB p-CSI may better quantify the growth benefits of bone sparing. The development of scoliosis and vertical growth suppression are multifactorial, and other etiologies for these growth abnormalities must be acknowledged. Burden of systemic disease, dose and duration of steroids used, chemotherapy, and hormonal dysfunction after RT may contribute to growth suppression. 25, 26 Cerebellar damage related to tumor or resection in posterior fossa tumors, vascular injury secondary to treatment, and uneven growth of paravertebral/paraspinal muscles may contribute to the development of scoliosis. Although these effects were not captured in the present study, many of them would be unlikely to manifest in the early post-RT time frame examined.
Both target volume strategies discussed have drawbacks. At our institution, WVB treatment allows a margin of 0.3 to 0.5 cm from the anterior aspect of the vertebral body to avoid dose delivery to anterior structures, resulting in nonuniform posterior-to-anterior dose exposure. Although no instances of lordosis were found to date, continued follow-up is needed to ascertain the longer-term implications of this margin. PVB p-CSI spares the majority of the vertebral body, but some dose is ultimately delivered to the posterior aspect of the vertebral body, possibly including ≥ 1 ossification centers in growing bone. 13 Although PVB p-CSI may be effective in reducing bone marrow toxicity and/or lateral curvature deformity, it remains unclear if PVB p-CSI mitigates growth inhibition in spite of this incidentally delivered dose. This effect may be compounded by possibility of increased RBE a few millimeters beyond the Bragg peak, known as the distal fall-off. 27 Our study found a significantly reduced growth suppression on univariate analysis but this was not reproduced on multivariate analysis. Other institutions have also reported use of alternate PVB irradiation strategies, 1 conformal thecal sac-only p-CSI using intensity-modulated proton therapy, and pencil beam scanning that spares ossification centers. 28, 29 In addition, novel imaging techniques such as dual energy CT and prompt gamma imaging may reduce range uncertainty and permit more precise dose delivery. 30, 31 Future studies should explore the effects of these tools, which may enable greater vertebral body sparing and reduced growth inhibition compared with conventional methods.
Limitations of our study include the small sample size, retrospective design, heterogenous patient population and management, substantial loss to quantitative follow-up, and probable confounders. However, to the best of our knowledge, this study is one of the first to use a large cohort to quantitatively estimate the early effects of p-CSI on growth changes, including spinal curvature deformity and ageadjusted height suppression. Further investigation into novel strategies to avoid bone exposure and reduce range uncertainty is warranted. In the absence of more conformal techniques used in clinical practice, however, our results suggest that a prospective trial evaluating PVB versus WVB p-CSI should be conducted to compare growth suppression, scoliosis, and short-term and long-term toxicity in children.
